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Background/Objective(s): Few studies have evaluated the therapeutic response among switchers of bi-
ologics in patients with psoriasis. We report our experience of ustekinumab in patients with psoriasis
who did not respond adequately to tumor necrosis factor (TNF) blockers treatment previously.
Methods: We retrospectively reviewed the therapeutic response of 20 patients with moderate-to-severe
psoriasis who had failed conventional treatment and had inadequate therapeutic response to previous
etanercept and/or adalimumab between 2012 and 2013. Inadequate therapeutic response is deﬁned by
<50% improvement in Psoriasis Area and Severity Index (PASI) compared to baseline. Ustekinumab
45 mg was given at Week 0, Week 4, and Week 16, and patients were evaluated for safety and effec-
tiveness at Week 0, Week 4, Week 16, and Week 28.
Results: Nineteen patients were followed to Week 16, and 14 patients to Week 28. At Week 16, at least
PASI 90, PASI 75, PASI 50, and PASI 25 responses were seen in three patients (3/19, 16%), four patients (4/
19, 26%), seven patients (7/19, 37%), and 13 patients (13/19, 68%), respectively. At Week 28, at least PASI
90, PASI 75, PASI 50, and PASI 25 responses were seen in two patients (2/14, 14%), three patients (3/14,
21%), seven patients (7/14, 50%), and 11 patients (11/14, 79%), respectively. No severe adverse events were
recorded in our series.
Conclusion: Despite a less favorable response compared to the pivotal studies, at least PASI 50 response
was achieved in 50% of patients at Week 28 after three injections of ustekinumab without serious
adverse events.
Copyright © 2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Psoriasis is a chronic inﬂammatory skin disease which signiﬁcantly
impairs quality of life.1 With the clariﬁcation of psoriasis patho-
genesis,2 biologic agents targeting either tumor necrosis factor
(TNF) blockers (such as etanercept3 and adalimumab4) or anti-
interleukin (IL)-12/23 (e.g., ustekinumab5) are increasingly used.
Switches between biologics are common, due to either safety or
efﬁcacy reasons, but few studies have evaluated the therapeuticy have no ﬁnancial or non-
atter or materials discussed
y, National Taiwan University
aiwan.
cal Association. Published by Elsevresponse among the switchers. This is a single-center, open-
labeled, retrospective study on the effects of ustekinumab in pa-
tients with moderate-to-severe psoriasis who had inadequate
response to previous etanercept and/or adalimumab.
Methods
This was a retrospective study in which we included 20 ustekinu-
mab users for chronic plaque type psoriasis (with ethics approval
from National Taiwan University Hospital, Taipei, Taiwan; approval
number 200712123R) during the period from May 2012 to July
2013. All of the patients had received subcutaneous etanercept
25 mg or 50 mg twice/week and/or adalimumab 40 mg every other
week previously in a tertiary medical center in Taiwan. All partic-
ipants fulﬁlled the reimbursement criteria for biologics use for
psoriasis patients which had: (1) baseline Psoriasis Area andier Taiwan LLC. All rights reserved.
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ustekinumab injection; and (2) inadequate response, contraindi-
cation or intolerance to at least two of the three conventional
systemic agents including methotrexate (at least 15 mg/week),
acitretin (0.3e1 mg/kg/day) and cyclosporine (up to 5 mg/kg/day)
in addition to narrow-band UV-B or psoralen UV-A phototherapy at
least twice/week for 3 months.6
Reasons for adalimumab or etanercept discontinuation were:
(1) inadequate therapeutic response, deﬁned by <50% improve-
ment in PASI compared to baseline: (2) loss of efﬁcacy deﬁned by
failure to maintain the original PASI 50 response; or (3) other
reasons such as signiﬁcantly impaired quality of life or short
remission duration after the previous TNF blockers. We collected
data on age, sex, disease duration of psoriasis, body height and
weight, body mass index (BMI), previous systemic treatments,
history of erythrodermic psoriasis, and psoriatic arthritis. Subcu-
taneous ustekinumab 45 mg was given at Week 0, Week 4, and
Week 16, and patients were evaluated for safety and PASI response
at Week 0, Week 4, Week 16, and Week 28.
We also evaluated the feasibility of predicting a PASI 50
response at Week 16 andWeek 28 by PASI improvement at Week 4.
Receiver operating characteristic (ROC) curves were used to
determine the level of PASI improvement that had optimal negative
predictive value (NPV), positive predictive value (PPV), sensitivity,
and speciﬁcity. The area under the ROC curve (AUC-ROC) at Week 4
was used to assess overall predictability at each time point. The
Youden Index (YI ¼ sensitivity þ speciﬁcity 1) was used to
determine the range of PASI responses that had the greatest pre-
dictive value.7
Before treatment, patients were checked for the presence of
hepatitis B virus (HBV) surface antigen (HBsAg), hepatitis C
virus(HCV) antibody, and latent tuberculosis (TB) by chest X-ray
and Quantiferon TB Gold, QFT-G, Cellestis Limited, Carnegie,
Victoria, Australia.8 HBV and HCV viral loads were checked on a
regular basis and antiviral treatment was provided as indicated.9,10
Patients with latent TB were treated concomitantly with 9-month
isoniazid prophylaxis.8Table 1 Basic demographics of the patients.










1 M/53 2 177/62/19.8 NBUVB, MTX, acitretin E
2 M/42 13 173/73/24.5 NBUVB, PUVA, MTX, CyS,
acitretin, hydroxyurea
E
3 M/32 17 183/110/32.8 NBUVB, MTX, acitretin E
4 F/34 28 160/65/25.2 NBUVB, MTX, no acitretin
due to future pregnancy plan;
no CyS due to hypertension)
E
5 F/48 8 152/67/29.1 PUVA, MTX, CyS, acitretin E
6 M/44 3 165/71/25.9 NBUVB, CyS, acitretin E
7 F/55 11 149/51/22.9 NBUVB, MTX, CyS, acitretin A
8 M/26 9 175/79/25.9 NBUVB, MTX, CyS, acitretin A
9 M/42 26 163/82/30.9 NBUVB, MTX, acitretin E
10 M/37 18 180/115/35.7 NBUVB, MTX, CyS, acitretin E
11 M/49 16 176/101/32.6 NBUVB, PUVA, MTX, acitretin E
12 M/35 23 170/81/28.0 NBUVB, MTX, CyS, acitretin E
13 F/60 12 158/70/28.0 NBUVB, MTX, acitretin E
14 F/32 12 172/68/22.9 NBUVB, MTX, CyS E
15 M/26 4 168/77/27.3 NBUVB, MTX, CyS, acitretin E
16 F/49 25 160/67/26.2 NBUVB, MTX, CyS, acitretin E
17 M/52 31 170/80/27.7 NBUVB, MTX, acitretin E
18 M/53 22 163/90/33.9 NBUVB, MTX, acitretin E
19 M/48 16 172/67/22.6 NBUVB, MTX, acitretin E
20 F/44 12 156/63/27.2 NBUVB, MTX, CyS, acitretin A
A¼ adalimumab; BH¼ body height; BMI¼ bodymass index; BW¼ bodyweight; CyS¼ cy
of efﬁcacy at the end of the treatment course; MTX ¼methotrexate; N ¼ nonresponder; N
life or short remission duration; PUVA ¼ psoralen and UV-A radiation.Results
Demographics
Among 20 patients enrolled in the study, the male-to-female ratio
was 13:7, median age was 44.0 years (range: 26e60 years), and
median disease duration was 14.5 years (range: 2e31 years). Eight
patients (40%) weighed <70 kg, and the average BMI was 27.4.
Sixteen patients (16/20, 80%) were overweight or obese (deﬁned by
BMI 24 according to the classiﬁcation of the Ministry of Health
and Welfare of Taiwan11). Eight patients (40%) had a history of
erythrodermic psoriasis, and 70% (14/20) of patients had psoriatic
arthritis. With regards to the status of hepatitis and TB, one patient
was an HCV carrier, four patients were HBV carriers, and two pa-
tients had a positive Quantiferon TB Gold test result (Table 1).Clinical response to previous biologics and causes of drug
discontinuation
Two patients (Patients 12 and 16) had three switches of biologics,
10 patients had two switches of biologics, and eight patients had
one switch of biologics. The causes of drug discontinuation are
depicted in Table 1. With regards to the cause of the ﬁrst biologic
discontinuation, 35% of patients were nonresponders, 40% of pa-
tients lost the efﬁcacy, and 20% of patients had an unsatisfactory
response that might still impair their quality of life. For the second,
50% were nonresponders, 33% of patients lost the efﬁcacy, and 17%
of patients had an unsatisfactory response. For the third, 50% of
patients were nonresponders, and 50% of patients lost the efﬁcacy.
The change of PASI scores are shown in Figures S1eS3. Based on
information of Table 2 and Figure S5, the response to biologics was
less satisfactory if there were more switches.
During the ﬁrst biological therapy, 14 patients (14/20, 70%) had
at least PASI 25, nine patients (9/20, 45%) had at least PASI 50, and
four patients (4/20, 20%) had at least PASI 75 response at Week 12.
AtWeek 24,14 patients (14/18, 78%) had at least PASI 25,11 patients










(N)/ A (N) þ  þ  þ
(N)/ A (N) þ þ  þ 
(L)     
(N)/ A (N)  þ   
(L)/ A (N) þ þ   
(L) þ e þ þ 
(N) e þ  þ 
(L) þ þ   
(O)/ A (L) þ þ   
(O)  þ   
(L)/ A (N)  þ   
(N)/ A (N)/ E (N) þ þ   
(L)/ A (L)  þ   
(O) þ    
(N)/ A (L)  þ   
(O) A (O)/ E (L)  þ   
(O)  þ   
(L)/ A (O)  þ  þ 
(L)/ A (L)     
(N)     
closporine; E¼ etanercept; HBV¼ hepatitis B virus; HCV¼ hepatitis C virus; L¼ loss
BUVB ¼ narrow band UV-B radiation; O ¼ other reasons such as impaired quality of
Table 2 Proportion of patients regarding Psoriasis Area and Severity Index (PASI) reduction during previous biological therapy and ustekinumab.
First biologic Second biologic Third biologic Ustekinumab
Week 12 Week 24 Week 12 Week 24 Week 12 Week 24 Week 16 Week 28
At least PASI 25 70 78 40 64 50 50 68 79
At least PASI 50 45 61 30 36 0 0 37 50
At least PASI 75 20 28 20 9 0 0 26 21
Data are presented as %.
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During the second biological therapy, four patients (4/10, 40%) had
at least PASI 25, three patients (3/10, 30%) had at least PASI 50, and
two patients (2/10, 20%) had at least PASI 75 at Week 12. At Week
24, seven patients (7/11, 64%) had at least PASI 25, four patients (4/
11, 36%) had at least PASI 50, and one patient had at least PASI 75 (1/
11, 9%); two patients lacked PASI scores atWeek 12, and one patient
lacked PASI score at Week 24. During the third biological therapy,
one patient (1/2, 50%) had at least PASI 25 in both Week 12 and
Week 24 (Table 2 and Figure S5).
Clinical response to ustekinumab
Because several participants had not reached the respective follow-
up time point at the study closure, only 19 patients could be fol-
lowed to Week 16, and 14 patients to Week 28. At Week 16, three
patients (3/19, 16%) had at least PASI 90, four patients (4/19, 26%)
had at least PASI 75, seven patients (7/19, 37%) had at least PASI 50,
and 13 patients (13/19, 68%) had at least PASI 25 response. In those
patients who had at least PASI 50, three patients (3/7, 43%) weighed
>70 kg, and six patients (6/7, 86%) were overweight or obese. At
Week 28, two patients (2/14, 14%) had at least PASI 90, three pa-
tients (3/14, 21%) had at least PASI 75, seven patients (7/14, 50%)
had at least PASI 50 and eleven patients (11/14, 79%) had at least
PASI 25 response. In those patients who had at least PASI 50, four
patients (4/7, 57%) weighed >70 kg, and ﬁve patients (5/7, 71%)
were overweight or obese. In addition to body weight and BMI,
number of switcher, history of psoriatic arthritis and erythrodermic
psoriasis, sex, and disease onset and duration did not signiﬁcantly
affect PASI response at Week 16 (data not shown). The change of
PASI scores is shown in Figure 1; PASI scores are shown in Table S1.Figure 1 Changes in Psoriasis Area and Severity InComparing the numbers of at least PASI 25 and at least PASI 50, the
clinical response to ustekinumab was worse than the ﬁrst biologic
agent but better than the ﬁrst switcher at the comparative time
points (Week 12 and Week 24 in etanercept and adalimumab;
Week 16 and Week 28 in ustekinumab) in our series. The propor-
tion of patients who had at least PASI 75 response was even higher
than those of all previous biologics (Table 2 and Figure S5). Mean
PASI reduction was 35.2% at Week 4, 42.6% at Week 16,
and 55.8% at Week 28 (Table 3).
Whenwe used PASI improvement atWeek 4 to predict if PASI 50
response could be obtained at Week 16, the AUC-ROC was 75%,
which showed acceptable predictability (Figure S4A) The YI
reached the maximum between PASI 30 and PASI 40. Achieving
PASI 30 was associated with high NPV (90%) but lower PPV (57%).
Whenwe used PASI improvement at Week 4 to predict if there was
PASI 50 at Week 28, the AUC-ROC was 67%, which showed less
favorable predictability (Figure S4B) The YI reached the maximum
between PASI 50 and PASI 60. Achieving  PASI 50 was associated
with moderate NPV (66%) but acceptable PPV (83%).
Eleven (46%) patients received systemic combination therapy,
which was subclassiﬁed into three entities. We deﬁned transitional
therapy as therapy given at a crossover period to prevent psoriasis
ﬂare, rescue therapy as therapy used alongside ustekinumab for <3
months or <50% of the total duration of the ustekinumab treat-
ment, and concomitant therapy as therapy used alongside usteki-
numab for >3 months or >50% of the total duration of the
ustekinumab treatment. Four patients received transitional ther-
apy, including methotrexate, acitretin, and narrow band UV-B ra-
diation. Three patients took methotrexate as rescue therapy, and
two patients took methotrexate as concomitant therapy. Another
two patients received both transitional and rescue therapy,dex (PASI) score during ustekinumab therapy.
Table 3 Mean Psoriasis Area and Severity Index (PASI) reduction during ustekinumab therapy.
No. Concomitant systemic therapy Compare Week 4 to
Week 0 mean PASI
score change (%)
PASI response at
Week 4 (<25, 25,
50, 75, 90, 100)
Compare Week 16 to







to Week 0 mean
PASI score change (%)
PASI response at
Week 28 (<25, 25,
50, 75, 90,100)
1 (1) T: NBUVB (Week 0e8)
(2) Adalimumab 40 mg
once (Week 8)
2.8 <25 36.4 25 32.4 <25
2 No 62.9 50 98 90 100 100
3 No 20 <25 þ3.7 <25 NA NA
4 No 52.2 50 68.8 50 18.5 <25
5 No 41.4 25 77 75 58.6 50
6 (1) T þ R: CyS (Week 0e4,
Week 9e13)
(2) R: NBUVB (Week 24, twice)
100 100 þ7.1 <25 NA NA
7 No 13.3 <25 100 100 82.9 75
8 No 43.8 25 26.8 25 48.5 25
9 C: MTX (Week 0e28) 34.1 25 þ30.8 <25 31.3 25
10 No NA NA 90.6 90 97.6 90
11 T: acitretin (Week 0e4) 33.5 25 70.3 50 67.1 50
12 No 57.0 50 47.2 25 30.8 25
13 R: MTX (Week 16e28) 19.3 <25 35.4 25 72.9 50
14 R: MTX (Week 16e28) 7.6 <25 47.8 25 74.5 50
15 (1) T þ R: MTX (Week 0-4,
Week 9e13)
(2) R: CyS (Week16e28)
12.2 <25 12.2 <25 22.5 <25
16 (1) R: MTX (Week 16e24)
(2) Etanercept 25 mg BIW
(Week 23e27)
49.4 25 50 50 42.9 25
17 No 28.5 25 20.9 <25 NA NA
18 T: NBUVB (Week 0, for twice) 30.0 25 23.8 <25 NA NA
19 T: MTX (Week 0e4) 22.5 <25 45.1 25 NA NA
20 C: MTX (Week 0e28) 37.6 25 NA NA NA NA
Mean 35.2 42.6 55.8
BIW ¼ twice per week; C ¼ concomitant therapy (therapy used alongside ustekinumab for >3 months or >half of the total duration of the ustekinumab treatment);
CyS ¼ cyclosporine; MTX ¼ methotrexate; NA ¼ not applicable; NBUVB ¼ narrow band UV-B radiation; R ¼ rescue therapy (therapy used alongside ustekinumab for <3
months or <half of the total duration of the ustekinumab treatment); T ¼ transitional therapy (therapy given at a crossover period to prevent psoriasis ﬂare).
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diation. Patient 1 also received subcutaneous adalimumab 40mg at
Week 8, and Patient 16 received subcutaneous etanercept 25 mg
twice/week at Weeks 23e27 due to poor disease control (Table 3).
Safety proﬁles of ustekinumab
No severe adverse events were recorded in our series. One patient
had upper respiratory infection (moderate, Patient 4), one patient
(Patient 9) with a history of chronic urticaria had one episode of
attack, and one patient (Patient 2) had recent onset of seborrheic
keratosis or verruca vulgaris on his dorsal hands.
Discussion
Biologics are increasingly used in the treatment of psoriasis. Results
from the pivotal trials show a comparable PASI 75 response of
adalimumab and ustekinumab5,12,13 and a head-to-head study
showed a more favorable PASI response of ustekinumab compared
to etanercept.11 However, failure in adalimumab or ustekinumab
does not preclude the treatment response of etanercept, and vice
versa.
Despite initial satisfactory results, biologic switch is often
encountered in daily clinical practice, but studies on the efﬁcacy
between biologic switchers weremostly conducted in patients with
rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis,
and mainly among TNF blockers.14e25 In time sequence, etanercept
followed by adalimumab and ustekinumab is approved and reim-
bursed for the treatment of psoriasis in Taiwan and most countries.
Thus, the switch ﬁrst from etanercept to adalimumab, and then to
ustekinumab is most often encountered. Most switches are due toeither primary or secondary drug failure, with fewer switches due
to adverse events.
In most countries, biologics are only reimbursed in patients with
psoriasis who have failed conventional treatment. However, the
exact criteria for reimbursement is different in regards to theneed of
baseline PASI and previous treatment.26 The interpretation of failure
and contraindication to prior treatment may also be different.
Thus, it is important to understand the actual effectiveness in these
highly selected patients, both for biologics-naïve and previous
biologics users. We previously reported our experience of switch
from etanercept to adalimumab.27 The result is less favorable
compared to the other reports of similar switches.28e32 In this
current study, a similar lower PASI response was found in patients
who switched from etanercept to adalimumab (i.e., second biologic
inTable 2 and Figure S5): 30%of patients had at least PASI 50 and20%
of patients had at least PASI 75 at Week 12; 36% of patients had at
least PASI 50 and only 9% of patients had at least PASI 75 atWeek 24.
There are fewer studies on switching from TNF blockers to
ustekinumab.12,33,34 In one Spanish study, 63% and 50% patients
who had previous exposure to TNF blockers had at least PASI 75
response at Week 12 and Week 24, respectively, which were lower
compared with TNF blocker-naïve patients, 85% of whom achieved
at least PASI 75 at each comparable time point.33 In another Danish
study, no statistically signiﬁcant differences were noticed between
TNF blocker-naïve and TNF blocker-exposed patients.34 In the
Active Comparator (CNTO1275/Enbrel) Psoriasis Trial (ACCEPT)
clinical trial, among patients who did not have a response to eta-
nercept, 49% had at least 75% improvement in the PASI score after
crossing over to 90 mg of ustekinumab for 12 weeks.12 Our study
showed less favorable results: only 26% of patients and 21% of pa-
tients had at least PASI 75 at Week 16 and Week 28, respectively.
T.-C. Wang et al. / Dermatologica Sinica 33 (2015) 5e10 9Regarding the efﬁcacy of ustekinumab based on body weight, in
the Spanish study,33 patients weighing <100 kg and treated with
the 45 mg dose had signiﬁcantly higher PASI 50 and response rates
at Week 24 than heavier patients treated with 90 mg, which was
inconsistent with previous pivotal studies which showed similar
response rates between the two groups.5,13,35 Most pivotal trials in
Western countries showed that higher dosages were needed for
heavier patients, and the prescribing information of ustekinumab
also used 100 kg as the cut-off value. However, in one Asian pivotal
study,35 70 kg (approximating the median Taiwanese population
weight) was used as the cut-off value based on the subgroup
analysis, and no apparent effect was found on the efﬁcacy of
ustekinumab under the dosage of 45 mg. The present study also
used 70 kg as the cut-off value and yielded similar results: neither
body weight nor BMI had a substantial inﬂuence on the effective-
ness of ustekinumab, which may have been biased by the small
sample size.
Several possibilities may explain the differences of the lower
PASI 75 response in the present study. Firstly, the stringent reim-
bursement criteria of biologics may select a subgroup of high-need
patients. Secondly, human leukocyte antigen (HLA) polymorphism
in Taiwan compared toWestern countries may also play a role.36e38
HLA-Cw6 was reported to be associated with a more favorable
response to ustekinumab,39 but HLA-Cw6 is underrepresented in
Taiwanese patients with psoriasis, especially in the moderate-to-
severe group. Thirdly, 40% of patients in our study had a history
of erythrodermic psoriasis. Biological drug survival rate and efﬁ-
cacy in patients with erythrodermic psoriasis appears to be lower
than in patients with plaque type psoriasis treated with either TNF-
a40 or IL-12/23 blockers.41e44 Fourthly, 70% of patients had psoriatic
arthritis which was shown to adversely affect the ustekinumab
efﬁcacy.13 Fifthly, patients who failed biological agents were more
likely to have poor response, as shown in a phase III study of
ustekinumab, where 36% PASI 75 responders at Week 28 were
previously treated with biological agents.13 However, our subgroup
analysis did not show statistically signiﬁcant differences of PASI
response regarding the number of switchers, and history of
erythrodermic psoriasis and psoriatic arthritis, which could be due
to low patient number. With regards to the safety of ustekinumab,
no serious adverse events were apparent in our study.
One recent study reported that early clinical response of ixeki-
zumab, an IL17A monoclonal antibody, could be served as a pre-
dictor of subsequent response to treatment.7 Our analysis by a
similar method showed that patients not achieving PASI 30 atWeek
4 were less likely to achieve PASI 50 at Week 16 based on YI ana-
lyses. However, our result is limited by the small sample sizes.
In our daily clinical practice, washout periods of systemic ther-
apies are required tomaintain optimal disease control in high-need
psoriasis patients.44 Previous studies reported that about 30e40%
of psoriasis patients received concurrent biologics and traditional
systemic agents in clinical practice.4,45,46 In the current study, 46%
of patients received systemic combination therapy, which may
complicate the interpretation of the results. However, 55% of them
did not reach PASI 50 response during the study period, revealing
their demand for concomitant therapies to control the intractable
disease.
Conclusion
This is a preliminary report of our experience of reimbursed uste-
kinumab users who had been treated previously with etanercept
or adalimumab for psoriasis in Taiwan. This study was limited by
the small sample size. However, it provides an important message
when a biologic switch is needed due to loss of efﬁcacy. Despite a
less favorable response compared to our previous pivotal study,ustekinumab may still be suggested as the preferred biologic for
psoriasis patients who had failed a previous TNF blocker, possibly
due to a different mode of action.References
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